Form 4: UroGen CMO Exercises RSUs, Sells Shares for Tax
Insider Transaction Report
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, exercised restricted stock units and sold a portion of the resulting shares to cover tax obligations.
Summary
- Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), reported two transactions involving the company's ordinary shares.
- On September 7, 2025, Mr. Schoenberg exercised 1,667 restricted stock units (RSUs), which converted into 1,667 ordinary shares. This transaction represents the second of three equal annual installments from an RSU grant made on September 7, 2023.
- Following the RSU conversion, his direct beneficial ownership of ordinary shares increased to 149,896.
- On September 8, 2025, Mr. Schoenberg sold 871 ordinary shares at a price of $19.11 per share.
- This sale was conducted to satisfy withholding tax obligations associated with the settlement of the restricted stock units.
- After these transactions, Mr. Schoenberg's direct beneficial ownership of ordinary shares stands at 149,025.
- He continues to beneficially own 1,667 restricted stock units, representing the final unvested installment of the original grant.
Sentiment
Score: 5
Explanation: Neutral, as Form 4 filings are mandatory disclosures of insider transactions and do not inherently convey positive or negative sentiment about the company's performance or outlook. The sale was for tax purposes, which is a common occurrence.
Future Outlook
This filing, a Form 4, details mandatory insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction filing (Form 4) and does not provide information relevant to broader industry trends or competitor analysis.
Stakeholder Impact
- Shareholders: The transactions represent a routine insider event involving the vesting of equity awards and a subsequent sale to cover tax obligations. This is a common practice and does not typically signal a change in management's confidence or significant impact on shareholder value.
Next Steps
- The final installment of 1,667 restricted stock units is expected to vest on September 7, 2026.
Key Dates
| Date | Description |
|---|---|
| 09/07/2023 | Grant date of 5,000 restricted stock units (RSUs) to Mark Schoenberg. |
| 09/07/2024 | First annual vesting date for the RSU grant. |
| 09/07/2025 | Second annual vesting date for 1,667 RSUs and their conversion into ordinary shares. |
| 09/08/2025 | Sale of 871 ordinary shares by Mark Schoenberg to cover tax obligations. |
| 09/09/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
UroGen Pharma, URGN, Mark Schoenberg, Chief Medical Officer, Form 4, Insider Transaction, Restricted Stock Units, RSU, Share Sale, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.